Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Khouri J, Faiman BM, Grabowski D, Mahfouz RZ, Khan SN, Wei W, Valent J, Dean R, Samaras C, Jha BK, Lazarus H, Campagnaro EL, Malek E, Reed J, Karam MA, Hamilton K, Fada S, Kalaycio M, Liu H, Sobecks R, Saunthararajah Y, Chew Y, Orloff M, Reu FJ. Khouri J, et al. Among authors: reu fj. Semin Hematol. 2021 Jan;58(1):45-55. doi: 10.1053/j.seminhematol.2020.12.004. Epub 2020 Dec 28. Semin Hematol. 2021. PMID: 33509443 Clinical Trial.
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H. Khan SN, et al. Among authors: reu fj. Leukemia. 2013 Jun;27(6):1301-9. doi: 10.1038/leu.2013.80. Epub 2013 Mar 14. Leukemia. 2013. PMID: 23486531
Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD. Hong S, et al. Among authors: reu f. Bone Marrow Transplant. 2016 May;51(5):732-4. doi: 10.1038/bmt.2015.326. Epub 2016 Jan 4. Bone Marrow Transplant. 2016. PMID: 26726941 No abstract available.
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, Przychodzen B, Rump M, Hobson S, Earl M, Sobecks R, Dean R, Reu F, Tiu R, Hamilton B, Copelan E, Lichtin A, Hsi E, Kalaycio M, Maciejewski J. Saunthararajah Y, et al. Among authors: reu f. J Clin Invest. 2015 Mar 2;125(3):1043-55. doi: 10.1172/JCI78789. Epub 2015 Jan 26. J Clin Invest. 2015. PMID: 25621498 Free PMC article. Clinical Trial.
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Khouri J, Reu F, Majhail NS, Gerds A, Jagadeesh D, Dean R, Sobecks R, Hamilton BK, Pohlman B, Hill BT, Corrigan D, Kalaycio M, Bolwell BJ, Liu HD. Khouri J, et al. Among authors: reu f. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e374-e376. doi: 10.1016/j.clml.2019.03.019. Epub 2019 Apr 8. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31053548 No abstract available.
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma.
Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Hasipek M, et al. Among authors: reu fj. Cancers (Basel). 2021 May 28;13(11):2649. doi: 10.3390/cancers13112649. Cancers (Basel). 2021. PMID: 34071205 Free PMC article.
37 results